Program Description
Although small cell lung cancer (SCLC) accounts for only 14% of lung cancer diagnoses in the United States, it remains the leading cause of cancer-related mortality. This high disease burden is compounded by an aggressive pathogenesis and early systemic spread, often leaving patients with limited time between initial response and inevitable progression. While platinum-based doublets combined with immune checkpoint inhibitors (ICIs) have established a new frontline standard for extensive-stage SCLC (ES-SCLC), many patients often develop resistance, and disease progression poses a significant challenge in management and treatment selection. Moreover, many patients do not receive subsequent lines of therapy following disease progression on frontline therapy. Given the high rate of relapse after first-line therapy, efforts are underway to identify more effective treatment strategies. This program will guide managed care and oncology pharmacists through the rapidly evolving landscape of targeted and novel therapies in ES-SCLC, with a particular focus on navigating recommendations for second-line treatment and beyond. The session will evaluate high-impact data for recently approved and emerging agents, with a focus on the operational complexities and multidisciplinary coordination required to safely administer these therapies, specifically product-specific adverse effects such as cytokine release syndrome, neurologic toxicities, and the management of treatment-induced myelosuppression. Presenters will discuss strategies for clinical pathway integration, site-of-care optimization, and managed care coordination to improve quality of life and outcomes for patients with ES-SCLC.
Target audience: Managed care pharmacists, Oncology Pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete
activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the evolving paradigms for subsequent lines of therapy following first-line treatment in extensive-stage small cell lung cancer (ES-SCLC), including the sequencing of novel and investigational agents
- Investigate the clinical utility of emerging biomarkers in guiding therapeutic decisions for advanced SCLC
- Optimize managed care strategies that support the clinical value and appropriate utilization of novel SCLC therapies within a patient-centered framework
Amanda S. Cass, PharmD, BCPS, BCOP
Clinical Pharmacist Specialist, Thoracic Oncology
Vanderbilt-Ingram Cancer Center
Nashville, TN
Abby Kim, PharmD, BCOP
Senior Director, Clinical Strategy and Oncology Specialty Solutions
Prime Therapeutics
Denver, CO
Accreditation
Pharmacy
Times Continuing Education™ is accredited by the
Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing
pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU)
under the ACPE universal activity number 0290-0000-26-091-H01-P. The activity
is available for CE credit through April 30, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Abby Kim, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:
Employee of PBM: Prime Therapeutics
Amanda S. Cass, PharmD, BCPS, BCOP, has the following relevant financial relationships with ineligible companies to disclose:
Consultant: Daiichi Sankyo, G1 Therapeutics Inc, Regeneron, Takeda
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Rose Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here